SCHEMBL5584023

SCHEMBL5584023

CCN1C(=O)NC(C)(C)C1=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.71
KMT2A Q03164 4/20 0.59
PDE4A P27815 1/20 0.52
PDE4B Q07343 1/20 0.52
PDE4C Q08493 1/20 0.52
PDE4D Q08499 1/20 0.52
MEN1 O00255 3/20 0.49
TSHR P16473 2/20 0.49
LMNA P02545 1/20 0.49
KDM4E B2RXH2 1/20 0.47
PADI4 Q9UM07 1/20 0.46
HSD17B10 Q99714 1/20 0.45
ALDH1A1 P00352 4/20 0.44
PLA2G7 Q13093 1/20 0.44
F2 P00734 1/20 0.42
ELANE P08246 1/20 0.42
CTSG P08311 1/20 0.42
CTRC Q99895 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
FPR2 P25090 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11378894 0.83 POLB (1.00) POLBKMT2APDE4APDE4BPDE4C
SCHEMBL11677768 0.83 POLB (0.74) POLBKMT2APDE4APDE4BPDE4C
SCHEMBL13753309 0.82 POLB (0.65) POLBKMT2APDE4APDE4BPDE4C
SCHEMBL11541792 0.79 POLB (0.68) POLBKMT2APDE4APDE4BPDE4C
SCHEMBL19423838 0.79 POLB (0.68) POLBKMT2APDE4APDE4BPDE4C
SCHEMBL561241 0.79 POLB (0.68) POLBKMT2APDE4APDE4BPDE4C
SCHEMBL27335612 0.79 POLB (0.68) POLBKMT2APDE4APDE4BPDE4C
SCHEMBL2713635 0.79 POLB (0.68) POLBKMT2APDE4APDE4BPDE4C
SCHEMBL11847614 0.79 POLB (0.68) POLBKMT2APDE4APDE4BPDE4C
SCHEMBL11694927 0.79 POLB (0.68) POLBKMT2APDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3394056-B1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC (US) 2021-04-14 EP disclosed
US-10689526-B2 N-halamines compounds as multifunctional additives BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-06-23 US disclosed
US-20190055414-A1 N-HALAMINES COMPOUNDS AS MULTIFUNCTIONAL ADDITIVES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-02-21 US disclosed
US-10138379-B2 N-halamines compounds as multifunctional additives BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-11-27 US disclosed
WO-2017165961-A1 SILANE-BASED ANTIMICROBIAL COATINGS AND METHODS OF MAKING AND USING THE SAME TRENT UNIVERSITY (CA) 2017-10-05 WO disclosed
US-20170273307-A1 SILANE-BASED ANTIMICROBIAL COATINGS AND METHODS OF MAKING AND USING THE SAME UNIV TRENT (CA) 2017-09-28 US disclosed
WO-2017112777-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC (US) 2017-06-29 WO disclosed
US-20170174869-A1 COMPOSITION, METHOD OF MANUFACTURING COMPOSITION, CURABLE COMPOSITION, CURED FILM, NEAR-INFRARED CUT FILTER, SOLID-STATE IMAGING DEVICE, INFRARED SENSOR, AND CAMERA MODULE FUJIFILM CORPORATION (JP) 2017-06-22 US disclosed
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC 2017-06-22 US disclosed
US-20150166796-A1 N-Halamines Compounds as Multifunctional Additives BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2015-06-18 US disclosed
US-20120174240-A1 ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE SANNA PIETRO P (US) 2012-07-05 US disclosed
US-8211932-B2 Organic compounds and their uses NOVARTIS AG (CH) 2012-07-03 US disclosed
US-8119854-B2 Role of proteoglycans in drug dependence Sanna, Pietro P. (US) 2012-02-21 US disclosed
US-8119854-B2 Role of proteoglycans in drug dependence Sanna, Pietro P. (US) 2012-02-21 US disclosed
US-20100331243-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2010-12-30 US disclosed
US-20100204159-A1 ORGANIC COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2010-08-12 US disclosed
US-20100199361-A1 Role of Proteoglycans in Drug Dependence Sanna, Pietro Paolo (US) 2010-08-05 US disclosed
US-20100199361-A1 Role of Proteoglycans in Drug Dependence Sanna, Pietro Paolo (US) 2010-08-05 US disclosed
US-7276520-B2 Bicyclic piperidine derivatives as melanocortin-4 receptor agonists MERCK & CO., INC. (US) 2007-10-02 US disclosed
US-20070062884-A1 N-halamines compounds as multifunctional additives BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166796-A1 N-Halamines Compounds as Multifunctional Additives NIT2, AAAS, NACA POLB 1145/4885KMT2A 303/4885PDE4A 2812/4885
US-20100331243-A1 ORGANIC COMPOUNDS AND THEIR USES OAT, OTC, AOX1 POLB 419/4885KMT2A 3407/4885PDE4A 3448/4885
US-20120174240-A1 ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE OGFR, CSGALNACT1, OPRL1 POLB 4760/4885KMT2A 3147/4885PDE4A 1761/4885
US-20170273307-A1 SILANE-BASED ANTIMICROBIAL COATINGS AND METHODS OF MAKING AND USING THE SAME CUTA, SMURF1, TET1 POLB 3134/4885KMT2A 1165/4885PDE4A 4576/4885
US-20100199361-A1 Role of Proteoglycans in Drug Dependence OGFR, CSGALNACT1, OPRL1 POLB 4760/4885KMT2A 3147/4885PDE4A 1761/4885
US-10138379-B2 N-halamines compounds as multifunctional additives NIT2, AAAS, NACA POLB 1145/4885KMT2A 303/4885PDE4A 2812/4885
US-20100204159-A1 ORGANIC COMPOUNDS AND THEIR USES OAT, OTC, AOX1 POLB 419/4885KMT2A 3407/4885PDE4A 3448/4885
US-10689526-B2 N-halamines compounds as multifunctional additives NIT2, AAAS, NACA POLB 1145/4885KMT2A 303/4885PDE4A 2812/4885
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE MAPK6, MAP3K6, MAPK4 POLB 1589/4885KMT2A 3544/4885PDE4A 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.